From GlobeNewswire: 2025-04-27 09:00:00

Relmada Therapeutics presented an abstract at the American Urology Association conference on April 28th, showcasing their innovative intravesical sustained release Gemcitabine Docetaxel combination therapy for bladder cancer. NDV-01, their lead investigational program, aims to improve outcomes for patients with High-Grade Non-Muscle Invasive Bladder Cancer by maximizing drug concentration, reducing side effects, and enhancing patient compliance. With a multi-billion dollar market opportunity in the U.S. and globally, NDV-01 could revolutionize bladder cancer treatment by offering a minimally invasive, effective therapy option. Learn more at www.relmada.com.



Read more at GlobeNewswire: UPDATE — Relmada Therapeutics To Present NDV-01 Data at